AbbVie to Buy Nimble Therapeutics for $200 Million
US biopharma AbbVie has signed an agreement to acquire US biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology for the rapid discovery and optimization of peptide candidates for a range of targets.
"The addition of Nimble's pipeline to AbbVie's existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity," said Jonathon Sedgwick, AbbVie’s senior vice president and global head of discovery research. "Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases."
"Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, Nimble's novel oral therapies will be well-positioned to reach more people living with autoimmune diseases," said Jigar Patel, founder and and CEO of Nimble Therapeutics.
Under the terms of the agreement, AbbVie will make a cash payment of $200 million at closing to acquire Nimble, subject to certain customary adjustments. Nimble's shareholders remain eligible for a potential payment, subject to the achievement of a development milestone. The proposed transaction is subject to customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
